Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant SHR-1210 (Camrelizumab) + Chemotherapy in Resectable NSCLC
NCT04108013Phase 2Unknown
- Sponsor
- Xuanwu Hospital
- Start
- Oct 2019
- Primary completion
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Xuanwu Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04108013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04108013.